Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience.

Zakrzewska JM, Palmer J, Bendtsen L, Di Stefano G, Ettlin DA, Maarbjerg S, Obermann M, Morisset V, Steiner D, Tate S, Cruccu G.

Trials. 2018 Dec 27;19(1):704. doi: 10.1186/s13063-018-3045-1.

2.

Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.

Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; study investigators.

Lancet Neurol. 2017 Apr;16(4):291-300. doi: 10.1016/S1474-4422(17)30005-4. Epub 2017 Feb 17.

PMID:
28216232
3.

A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgia.

Tanaka BS, Zhao P, Dib-Hajj FB, Morisset V, Tate S, Waxman SG, Dib-Hajj SD.

Mol Med. 2016 Sep;22:338-348. doi: 10.2119/molmed.2016.00131. Epub 2016 Aug 3.

4.

Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.

Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, Tate S, Gunn K.

Trials. 2013 Nov 23;14:402. doi: 10.1186/1745-6215-14-402.

5.

Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease.

Di Sabatino A, Rovedatti L, Kaur R, Spencer JP, Brown JT, Morisset VD, Biancheri P, Leakey NA, Wilde JI, Scott L, Corazza GR, Lee K, Sengupta N, Knowles CH, Gunthorpe MJ, McLean PG, MacDonald TT, Kruidenier L.

J Immunol. 2009 Sep 1;183(5):3454-62. doi: 10.4049/jimmunol.0802887. Epub 2009 Jul 31.

6.

Deriving uncertainty factors for threshold chemical contaminants in drinking water.

Ritter L, Totman C, Krishnan K, Carrier R, V├ęzina A, Morisset V.

J Toxicol Environ Health B Crit Rev. 2007 Oct;10(7):527-57.

PMID:
17934949
7.

The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity.

Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ.

J Neurosci. 2006 Dec 13;26(50):12852-60.

8.

TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation.

Lappin SC, Randall AD, Gunthorpe MJ, Morisset V.

Eur J Pharmacol. 2006 Jul 1;540(1-3):73-81. Epub 2006 May 6.

PMID:
16737693
9.

Dynamic balance of metabotropic inputs causes dorsal horn neurons to switch functional states.

Derjean D, Bertrand S, Le Masson G, Landry M, Morisset V, Nagy F.

Nat Neurosci. 2003 Mar;6(3):274-81.

PMID:
12592405
10.

Possible mechanisms of cannabinoid-induced antinociception in the spinal cord.

Morisset V, Ahluwalia J, Nagy I, Urban L.

Eur J Pharmacol. 2001 Oct 19;429(1-3):93-100. Review.

PMID:
11698030
12.
13.
14.

Supplemental Content

Loading ...
Support Center